PMID- 33751184
OWN - NLM
STAT- MEDLINE
DCOM- 20220222
LR  - 20220531
IS  - 1613-7671 (Electronic)
IS  - 0043-5325 (Linking)
VI  - 134
IP  - 3-4
DP  - 2022 Feb
TI  - Is there a correlation between hypomagnesemia linked to long-term proton pump 
      inhibitor use and the active agent?
PG  - 104-109
LID - 10.1007/s00508-021-01834-x [doi]
AB  - BACKGROUND: One of the electrolyte disorders considered to be linked to proton 
      pump inhibitors (PPI) use is hypomagnesemia. The aim of this study was to assess 
      the incidence of hypomagnesemia linked to long-term PPI use and the correlation 
      with active agents. METHODS: The study included 305 patients aged over 18 years 
      with PPI use of 1 year or longer and attending the internal diseases clinic for 
      any reason from April 2019 to December 2019. A survey study was performed about 
      the demographic characteristics and PPI use of patients. Laboratory parameters, 
      such as the hemogram, magnesium, phosphorus, calcium and vitamin B12 
      concentrations were recorded. Magnesium concentrations were measured by a 
      colorimetric method. RESULTS: Of the patients 140 (45.9%) were female and 165 
      (54.1%) were male. The most commonly used PPI active agent was pantoprazole. The 
      duration of PPI use varied from 1-25 years with a mean of 4.31 +/- 4.52 years. Of 
      the patients 51.5% reported no medication side effects. The most commonly 
      observed side effect was constipation (n = 98, 32.1%). The mean magnesium 
      concentration was 1.95 +/- 0.02 mg/dL. Hypomagnesemia was identified in 65 (21.3%) 
      patients and the incidence increased as age and duration of use increased. 
      Patients using omeprazole had significantly lower magnesium levels compared to 
      patients using pantoprazole, rabeprazole, esomeprazole and lansoprazole. 
      CONCLUSION: In light of the data obtained it was concluded that hypomagnesemia 
      linked to PPI use is associated with the type of PPI. While patients using 
      rabeprazole had the lowest rates, those using omeprazole had significantly higher 
      rates of hypomagnesemia. Additionally, there was a proportional correlation 
      between age and duration of use with the risk of development of hypomagnesemia.
CI  - (c) 2021. Springer-Verlag GmbH, AT part of Springer Nature.
FAU - Aydin Yoldemir, Sengul
AU  - Aydin Yoldemir S
AD  - Department of Internal Medicine, University of Health Sciences Okmeydani Training 
      and Research Hospital, Istanbul, Turkey. sengulaydinn@gmail.com.
FAU - Zeren Ozturk, Guzin
AU  - Zeren Ozturk G
AD  - Departament of Family Medicine, University of Health Sciences, Istanbul Sisli 
      Hamidiye Etfal Health Practice and Research Center, Istanbul, Turkey.
FAU - Akarsu, Murat
AU  - Akarsu M
AD  - Department of Internal Medicine, University of Health Sciences Okmeydani Training 
      and Research Hospital, Istanbul, Turkey.
FAU - Ozcan, Mustafa
AU  - Ozcan M
AD  - Department of Internal Medicine, University of Health Sciences Okmeydani Training 
      and Research Hospital, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210322
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - 0 (Proton Pump Inhibitors)
RN  - I38ZP9992A (Magnesium)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - *Magnesium
MH  - Male
MH  - Middle Aged
MH  - Omeprazole
MH  - *Proton Pump Inhibitors/adverse effects
OTO - NOTNLM
OT  - Aged
OT  - Long-term use
OT  - Magnesium
OT  - Omeprazole
OT  - Proton pump inhibitors
EDAT- 2021/03/23 06:00
MHDA- 2022/02/23 06:00
CRDT- 2021/03/22 19:02
PHST- 2020/02/28 00:00 [received]
PHST- 2021/02/13 00:00 [accepted]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2022/02/23 06:00 [medline]
PHST- 2021/03/22 19:02 [entrez]
AID - 10.1007/s00508-021-01834-x [pii]
AID - 10.1007/s00508-021-01834-x [doi]
PST - ppublish
SO  - Wien Klin Wochenschr. 2022 Feb;134(3-4):104-109. doi: 10.1007/s00508-021-01834-x. 
      Epub 2021 Mar 22.